LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
19 hedge funds and large institutions have $6.77M invested in LAVA Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 3 closing their positions.
164% more call options, than puts
Call options by funds: $174K | Put options by funds: $66K
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.01% less ownership
Funds ownership: 14.31% → 14.3% (-0.01%)
5% less funds holding
Funds holding: 20 → 19 (-1)
46% less capital invested
Capital invested by funds: $12.5M → $6.77M (-$5.76M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$175K |
| 2 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
+$121K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$81.3K |
| 4 |
Two Sigma Investments
New York
|
+$80.3K |
| 5 |
Two Sigma Advisers
New York
|
+$39.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$341K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$60.9K |
| 3 |
AWG
Alpha Wave Global
New York
|
-$54.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$43K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$39.6K |
LVTX Hedge Fund Activity: Q2 2024 in Review
19 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q2 2024, worth a combined $6.77M — down 46% from $12.5M a quarter earlier.
Fund positioning in LVTX was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $175K. The largest seller was Walleye Capital, cutting an estimated $341K.
- 19 institutional investors held LAVA Therapeutics (LVTX) as of Q2 2024, down from 20 in Q1 2024.
- Funds reported $6.77M of LAVA Therapeutics stock for Q2 2024, down 46% quarter-over-quarter.
- 3 funds opened new LAVA Therapeutics positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest LAVA Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $175K added.
- The largest LAVA Therapeutics seller in Q2 2024 was Walleye Capital, an estimated $341K sold.
Based on aggregated 13F filings for Q2 2024.